Protagonist Therapeutics (PTGX) Change in Accured Expenses (2015 - 2026)

Protagonist Therapeutics has reported Change in Accured Expenses for 12 years, with the latest figure at -$10.8 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 8.67% year-over-year to -$10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (up 220.24% YoY) and the FY2025 annual result came in at $4.6 million, up 6.69% from the prior year.
• Change in Accured Expenses retreated to -$10.8 million in Q1 2026 per PTGX's latest filing, from $5.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $7.5 million in Q3 2025 and troughed at -$11.8 million in Q1 2025.
• A 5-year average of -$1.2 million and a median of -$1.4 million in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses tumbled 659.29% in 2022, then surged 353.05% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$4.6 million in 2022, then retreated by 16.35% to -$5.3 million in 2023, then soared by 160.47% to $3.2 million in 2024, then surged by 67.57% to $5.4 million in 2025, then tumbled by 299.52% to -$10.8 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$10.8 million, $5.4 million, and $7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.